PELTHOS THERAPEUTICS/$PTHS
13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX
About PELTHOS THERAPEUTICS
Pelthos Therapeutics Inc is a biopharmaceutical company committed to commercializing safe and efficacious therapeutic products to help patients with unmet treatment burdens. The Company currently has three U.S. Food and Drug Administration (FDA) approved products in its commercial portfolio, in various stages of commercialization, including ZELSUVMITM, XEPI, and XEGLYZE. The company operates in two reporting segments: the sale, promotion, and commercialization of approved commercial products, the Commercial Operations segment, and research and development activities related to developing a novel and proprietary class of NaV blockers that target the body's peripheral nervous system; and supportive activities to expand the NITRICIL nitric oxide-based technology.
Ticker
$PTHS
Sector
Primary listing
AMEX
Employees
92
Headquarters
Website
PTHS Metrics
BasicAdvanced
$94m
-
-$20.19
3.33
-
Price and volume
Market cap
$94m
Beta
3.33
52-week high
$54.29
52-week low
$13.76
Average daily volume
22k
Financial strength
Current ratio
2.792
Quick ratio
1.747
Long term debt to equity
148.969
Total debt to equity
150.792
Interest coverage (TTM)
-8.16%
Profitability
Gross margin (TTM)
75.16%
Net profit margin (TTM)
-186.24%
Operating margin (TTM)
-154.01%
Effective tax rate (TTM)
12.53%
Revenue per employee (TTM)
$300,000
Management effectiveness
Return on assets (TTM)
-36.45%
Return on equity (TTM)
-333.84%
Valuation
Price to revenue (TTM)
2.491
Price to book
2.59
Price to tangible book (TTM)
-3.25
Price to free cash flow (TTM)
-1.951
Free cash flow yield (TTM)
-51.26%
Free cash flow per share (TTM)
-13.845
Growth
Earnings per share change (TTM)
62.76%
3-year earnings per share growth (CAGR)
-10.36%
PTHS News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs